Euglycemic DKA: Ketoacidosis Hiding Behind a Normal Blood Sugar

⚕️ Medical Disclaimer: This content is for educational purposes only and is intended for licensed healthcare professionals. It does not constitute medical advice and should not replace clinical judgment, facility protocols, or physician orders. Always verify medications, doses, and procedures with your institution's guidelines.

Part of the ICU Emergencies Hub — browse every related guide in one place.

This article was created with AI assistance.
The short answer: Diabetic ketoacidosis is defined by acidosis and ketones, not by a high glucose — and a whole class of diabetes drugs, the SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin and their "-flozin" relatives), can produce full DKA with a glucose that is normal or only mildly elevated. Because the number every clinician instinctively watches looks reassuring, euglycemic DKA is missed or treated late. The rule that saves these patients is simple: in a sick diabetic on an SGLT2 inhibitor, check the anion gap and ketones even when the glucose is normal, and do not let a normal sugar talk you out of the diagnosis.

For years the mental shortcut for DKA was "high sugar plus sick." SGLT2 inhibitors broke that shortcut. They are excellent, widely prescribed drugs for diabetes, heart failure, and kidney disease, but they change the presentation of ketoacidosis in a way that catches experienced nurses off guard. Understanding why the glucose stays low is the key to never missing it.

The Mechanism: The Kidney Dumps the Sugar, the Body Still Makes Ketones

SGLT2 inhibitors work by blocking glucose reabsorption in the kidney, so the patient spills large amounts of glucose into the urine. That lowers blood glucose — the therapeutic effect — but it also removes the visual cue clinicians rely on. Meanwhile, the same drug lowers insulin levels and nudges the body toward burning fat for fuel, which generates ketones. When a stressor is added (infection, surgery, fasting, dehydration, alcohol), the body ramps into ketone production while the kidney quietly keeps dumping glucose. The result is a patient in genuine ketoacidosis whose blood sugar never rises to the classic 400-600 range.

Operating principle: glucose is what SGLT2 inhibitors control; ketones and acid are what they do not. So in these patients, glucose is the least reliable marker of DKA, and the anion gap plus ketones become the diagnosis.

Why It Gets Missed

The miss is almost always cognitive. A diabetic patient arrives nauseated, short of breath, or vomiting after surgery. The fingerstick reads 140-180 — normal to mildly high — and the team moves on to other explanations for the symptoms. The tachypnea gets attributed to anxiety or pain rather than being recognized as the Kussmaul breathing of a body blowing off acid. Hours pass while the pH keeps dropping. The single habit that prevents this is to draw a venous blood gas and check ketones on any unwell diabetic taking a "-flozin," regardless of the glucose.

A normal glucose does not rule out DKA in an SGLT2-inhibitor patient. If the patient is on empagliflozin, dapagliflozin, canagliflozin, or ertugliflozin and is acidotic, ketotic, or unexplainedly sick, treat the acid-base picture, not the fingerstick. Anchoring on a reassuring glucose is the classic error.

The Triggers: Anything That Stresses Fuel Supply

Euglycemic DKA is nearly always provoked. The common triggers all share a theme of reduced carbohydrate intake or increased metabolic demand: surgery and the perioperative fast, acute illness or infection, dehydration, low-carbohydrate or ketogenic dieting, heavy alcohol use, and abrupt reductions in insulin. The perioperative setting is so consistent a trigger that guidance recommends stopping SGLT2 inhibitors several days before planned surgery. An ICU nurse admitting a post-operative diabetic on one of these drugs should have euglycemic DKA on the radar from the first set of labs.

Classic (hyperglycemic) DKAEuglycemic DKA
Glucose often 400-800+Glucose normal to mildly high (<250)
Diagnosis suggested by the numberNumber is falsely reassuring
Usually type 1 or new diagnosisOften on an SGLT2 inhibitor
Anion gap high, ketones highAnion gap high, ketones high (same)

Note the last row: the acid-base and ketone picture is identical. That is the whole point — euglycemic DKA is real DKA with the glucose subtracted out. The distinction between DKA and HHS still turns on gap and ketones, and the same reasoning applies here.

The Treatment That Confuses New Nurses

Treating euglycemic DKA looks paradoxical at first: the patient needs an insulin infusion to shut off ketone production, but their glucose is already normal, so insulin alone would cause hypoglycemia. The answer is to run insulin and dextrose together — the dextrose keeps the glucose safe while the insulin does its real job of turning off ketogenesis and closing the anion gap. New nurses often hesitate to hang dextrose on a DKA patient because it feels backwards; here it is essential.

Euglycemic DKA treatment logic:
  Insulin infusion -> stops ketone production, closes the gap
  Dextrose (D5/D10) -> prevents hypoglycemia so insulin can run
  Fluids + potassium -> same rules as classic DKA
Endpoint: resolution of ACIDOSIS/gap, not the glucose number

The treatment endpoint is the same conceptual target as any DKA: you are treating until the anion gap closes and the acidosis resolves, not until the glucose hits a number. Potassium is monitored and replaced on the usual DKA rules, because insulin drives potassium into cells regardless of the glucose level. The management overlaps heavily with a standard DKA insulin drip, with the single crucial modification of concurrent dextrose from the start.

Stop the SGLT2 inhibitor. The offending drug should be held during the acute illness. Restarting it is a later, outpatient decision — during the DKA it only perpetuates the glucosuria and ketosis.

What the Nurse Watches

Beyond the drip, monitoring mirrors classic DKA with a few euglycemic-specific cautions. Follow serial venous blood gases and the anion gap to confirm the acidosis is actually improving. Watch potassium closely. And critically, do not down-titrate or stop the insulin when the glucose drifts low — instead increase the dextrose, because stopping insulin re-opens the ketone tap. The general diabetes-emergency monitoring bundle applies, but the discipline of chasing the gap rather than the glucose is what defines good euglycemic DKA care.

The Bottom Line

Euglycemic DKA is ordinary ketoacidosis wearing a disguise: the SGLT2 inhibitor spills glucose into the urine so the blood sugar looks fine while the patient acidifies. The diagnosis lives in the anion gap and ketones, not the fingerstick, and the treatment is insulin plus dextrose run together until the acidosis clears. Any unwell diabetic on a "-flozin" — especially after surgery, fasting, or infection — deserves a blood gas and ketones regardless of a normal glucose. The nurse who refuses to be reassured by a normal sugar is the one who catches this before the pH falls.

Related: DKA vs HHS | DKA insulin drip guide | Insulin drip to subQ transition | Diabetes emergencies guide

Get The ICU Notebook Newsletter

Clinical tools and career insights for ICU nurses. One email per week, no fluff.

Yes, send it free

No spam. Unsubscribe any time.